Novo Nordisk's Raised Forecast Fails to Change Debate Over Its Obesity Business Novo Nordisk's recent earnings report has again raised more questions than it answers about the company's ability to sustain growth in a highly competitive market.
Despite better than expected quarterly numbers and increased guidance, the underlying narrative remains complex.
The Danish pharmaceutical giant's weight loss business is facing unprecedented challenges from rival companies like Eli Lilly, which has rapidly gained market share with its own offerings, Mounjaro and Zepbound.